PACIFIC THERAPEUTICS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT

VANCOUVER, BRITISH COLUMBIA- (April 26, 2013,) – Pacific Therapeutics Ltd. (the "Company") announced that it will increase the size of the previously announced non-brokered Private Placement from 2,000,000 up to 4,000,000 units (the "units") and proceed with the Private Placement of 4,000,000 units at a price of $0.05 per unit for gross proceeds of up to $200,000. Each unit is comprised of one common share of the Issuer (a "Share") and one-half share purchase warrant (a "Warrant"). Each Whole warrant entitles the Subscriber to purchase one additional common share of the Issuer for a period of 24 months from the closing date at a price of $0.22 per share.

All securities issued in connection with the Private Placement will be subject to a four-month hold period. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities. A finder's fee may be payable in accordance with regulatory policies.

The Company intends to use the proceeds for general working capital and a portion for research and development.

The Issuer remains focused on the repurposing and reformulation of existing FDA approved drugs for large markets.

ABOUT PACIFIC THERAPEUTICS LTD.

Pacific Therapeutics Ltd is a clinical stage specialty pharmaceutical company focused on the identification and development of drug candidates suitable for reformulation and repurposing. Its lead programs focus diseases of excessive scarring (fibrosis).

The Company's lead drug candidate for fibrosis, PTL-202 is a combination of Pentoxifylline (a FDA approved drug used for treating leg cramps) and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant.

PTL-202 has completed phase 1 trials in humans. The positive results from the phase 1 clinical trial of PTL-202 has led to further development of the product for treating fibrosis such as Idiopathic Pulmonary Fibrosis and Liver Cirrhosis.

The Company's strategy includes reformulating approved drugs to increase efficacy and patient compliance, while reducing side effects, as well as completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles.

409 Granville Street Suite 1023, Vancouver, BC V6C 1T2
Ph: (604) 738-1049 Fax: (604) 738-1094

For further information visit our website at www.pacifictherapeutics.com or email us at doug.unwin@pacifictherapeutics.com On Behalf of the Board of Directors

Douglas H. Unwin, CEO & President
(604) 738-1049
doug.unwin@pacifictherapeutics.com

FORWARD LOOKING STATEMENTS

Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.